Consensus Nautilus Biotechnology, Inc.

Equities

NAUT

US63909J1088

Delayed Nasdaq Other stock markets 03:01:29 2024-05-21 pm EDT			5-day change	1st Jan Change
2.78 ^USD	-2.11%		-2.45%	-6.69%

Apr. 30	Transcript : Nautilus Biotechnology, Inc., Q1 2024 Earnings Call, Apr 30, 2024
Apr. 30	Nautilus Biotechnology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Evolution of the average Target Price on Nautilus Biotechnology, Inc.

Price target over the last 5 years

History of analyst recommendation changes

0e8fd3b3f75852603aa09213dad683.3ZLPOU5F9wDL849rS0CKC92MYn6aLl-UfBpYOtpGiyQ.jOe8UQEyuFCduNoAKDnoU7q5BEaiQmfSNUUVUJwu6U3szbd3ejGWaobL2g~5aa2260fdfc8f5848a0881c91a485817

Analyst Recommendations on Nautilus Biotechnology, Inc.

Goldman Sachs Halves Price Target on Nautilus Biotechnology to $2 From $4 Amid Product Launch Delay; Neutral Rating Kept	22-08-04	MT
Morgan Stanley Lowers Nautilus Biotechnology's Price Target to $6 From $8, Maintains Equalweight Rating	22-08-03	MT
Goldman Sachs Adjusts Nautilus Biotechnology's Price Target to $4 from $5, Keeps Neutral Rating	22-07-14	MT
Goldman Sachs Adjusts Nautilus Biotechnology's Price Target to $5 from $9, Keeps Neutral Rating	22-04-13	MT
Morgan Stanley Initiates Nautilus Biotechnology at Equalweight With $8 Price Target, Sees Commercialization Key to Unlocking Upside	22-01-06	MT
Cowen Initiates Coverage on Nautilus Biotechnology With Outperform Rating	21-11-02	MT
NAUTILUS BIOTECHNOLOGY : Goldman Sachs Starts Nautilus Biotechnology at Neutral With $10 Price Target	21-08-04	MT
NAUTILUS BIOTECHNOLOGY : Jefferies Starts Nautilus Biotechnology at Buy With $13 Price Target	21-07-13	MT
NAUTILUS BIOTECHNOLOGY : Jefferies Initiates Coverage on Nautilus Biotechnology With Buy Rating, $13 Price Target	21-07-13	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

2.84 USD

Average target price

4.25 USD

Spread / Average Target

+49.65%

High Price Target

5 USD

Spread / Highest target

+76.06%

Low Price Target

2.75 USD

Spread / Lowest Target

-3.17%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Nautilus Biotechnology, Inc.

Goldman Sachs
Morgan Stanley
Cowen
Jefferies & Co.

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar